Bio-Techne purchases Zephyrus Biosciences
Zephyrus Biosciences provides research tools to enable protein analysis at the single cell level
Bio-Techne has acquired Zephyrus Biosciences, which will be integrated into the former's Protein Platforms Division.
No financial details have been disclosed.
Zephyrus Biosciences provides research tools to enable protein analysis at the single cell level. Addressing the growing single cell analysis market, the firm's first product, the Z1 system, enables Western blotting on individual cells for the first time. Researchers will use the firm's products to gain new insights into the biology of cancer, stem cells, neurology, and human disease and development.
The firm was spun out from Dr Amy Herr's laboratory at U.C. Berkeley in 2013.
Charles Kummeth, President and Chief Executive of Bio-Techne, said the acquisition demonstrates the firm's continued interest in Western blotting, a vital technique in protein identification and characterisation.
'This new technology brings this technique to the single cell level, allowing us to address both homogenous sample populations with our Simple Western platforms and now heterogeneous populations at the single cell level with Zephyrus and the Z1 System,' he said.
Zephyrus's co-founder and Chief Executive Kelly Gardner, added: 'This deal provides an excellent path forward for commercialisation of the single cell Western Blot (scWestern Blot) technology. The market reach of Bio-Techne will enable Zephyrus to rapidly reach the broad market of researchers who need to study proteins at the single cell level.'
Gardner and other members of the Zephyrus team will remain in place following the closing of the transaction.
